Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

August 4, 2025

Study Completion Date

August 4, 2025

Conditions
Gastrointestinal Malignancies
Interventions
DRUG

Lurbinectedin 4 MG Injection [Zepzelca]

"Lurbinectedin will be administered with a minimum total volume of 100 mL of solution for infusion (either on 5% glucose or 0.9% sodium chloride).~Lurbinectedin will be administered intravenously through peripheral or central lines at a dose of 3.2 mg/m2 at a fixed infusion rate."

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

HonorHealth Research Institute

OTHER